vs
カーディナルヘルス（BTSG）とTapestry, Inc.（TPR）の財務データ比較。上の社名をクリックして会社を切り替えられます
カーディナルヘルスの直近四半期売上が大きい（$3.6B vs $2.5B、Tapestry, Inc.の約1.4倍）。Tapestry, Inc.の純利益率が高く（22.4% vs 2.2%、差は20.3%）。カーディナルヘルスの前年同期比売上増加率が高い（16.3% vs 14.0%）。Tapestry, Inc.の直近四半期フリーキャッシュフローが多い（$1.0B vs $193.9M）。過去8四半期でTapestry, Inc.の売上複合成長率が高い（29.9% vs 17.4%）
カーディナルヘルスは米国の多国籍医療サービス企業で、米国企業収益ランキング第15位に位置し、本社をオハイオ州ダブリンに置く。医薬品・医療製品流通で10万拠点以上にサービスを提供するほか、手術着や手袋、流体管理製品などを製造し、最大級の放射性医薬品ネットワークも運営する。
Tapestry, Inc.はアメリカ発の大手多国籍ラグジュアリーファッション持株会社で、Coach、Kate Spade New York、Stuart Weitzmanの3つの代表的なライフスタイルブランドを保有し、高級ハンドバッグ、アパレル、靴、アクセサリー、香水などを世界中の消費者に提供しています。
BTSG vs TPR — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $3.6B | $2.5B |
| 純利益 | $77.1M | $561.3M |
| 粗利率 | 11.6% | 75.5% |
| 営業利益率 | 3.0% | 28.6% |
| 純利益率 | 2.2% | 22.4% |
| 売上前年比 | 16.3% | 14.0% |
| 純利益前年比 | 381.8% | 80.8% |
| EPS（希薄化後） | $0.34 | $2.68 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $3.6B | $2.5B | ||
| Q3 25 | $3.3B | $1.7B | ||
| Q2 25 | $3.1B | $1.7B | ||
| Q1 25 | $2.9B | $1.6B | ||
| Q4 24 | $3.1B | $2.2B | ||
| Q3 24 | $2.9B | $1.5B | ||
| Q2 24 | $2.7B | $1.6B | ||
| Q1 24 | $2.6B | $1.5B |
| Q4 25 | $77.1M | $561.3M | ||
| Q3 25 | $55.8M | $274.8M | ||
| Q2 25 | $28.2M | $-517.1M | ||
| Q1 25 | $29.5M | $203.3M | ||
| Q4 24 | $16.0M | $310.4M | ||
| Q3 24 | $-8.2M | $186.6M | ||
| Q2 24 | $19.9M | $159.3M | ||
| Q1 24 | $-45.8M | $139.4M |
| Q4 25 | 11.6% | 75.5% | ||
| Q3 25 | 11.8% | 76.3% | ||
| Q2 25 | 11.9% | 76.3% | ||
| Q1 25 | 11.8% | 76.1% | ||
| Q4 24 | 13.8% | 74.4% | ||
| Q3 24 | 14.0% | 75.3% | ||
| Q2 24 | 14.2% | 74.9% | ||
| Q1 24 | 14.3% | 74.7% |
| Q4 25 | 3.0% | 28.6% | ||
| Q3 25 | 2.6% | 19.3% | ||
| Q2 25 | 1.5% | -33.9% | ||
| Q1 25 | 1.8% | 16.0% | ||
| Q4 24 | 2.6% | 22.4% | ||
| Q3 24 | 2.0% | 16.7% | ||
| Q2 24 | 2.3% | 14.8% | ||
| Q1 24 | 0.3% | 13.8% |
| Q4 25 | 2.2% | 22.4% | ||
| Q3 25 | 1.7% | 16.1% | ||
| Q2 25 | 0.9% | -30.0% | ||
| Q1 25 | 1.0% | 12.8% | ||
| Q4 24 | 0.5% | 14.1% | ||
| Q3 24 | -0.3% | 12.4% | ||
| Q2 24 | 0.7% | 10.0% | ||
| Q1 24 | -1.8% | 9.4% |
| Q4 25 | $0.34 | $2.68 | ||
| Q3 25 | $0.26 | $1.28 | ||
| Q2 25 | $0.13 | $-2.30 | ||
| Q1 25 | $0.14 | $0.95 | ||
| Q4 24 | $0.11 | $1.38 | ||
| Q3 24 | $-0.04 | $0.79 | ||
| Q2 24 | $0.10 | $0.67 | ||
| Q1 24 | $-0.26 | $0.60 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $88.4M | $1.1B |
| 総負債低いほど良い | $2.5B | $2.4B |
| 株主資本純資産 | $1.9B | $551.2M |
| 総資産 | $6.4B | $6.5B |
| 負債/資本比率低いほどレバレッジが低い | 1.34× | 4.32× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $88.4M | $1.1B | ||
| Q3 25 | $140.3M | $743.2M | ||
| Q2 25 | $70.1M | $1.1B | ||
| Q1 25 | $52.3M | $1.1B | ||
| Q4 24 | $61.3M | $1.0B | ||
| Q3 24 | $36.0M | $7.3B | ||
| Q2 24 | $25.0M | $7.2B | ||
| Q1 24 | $58.0M | $7.4B |
| Q4 25 | $2.5B | $2.4B | ||
| Q3 25 | $2.5B | $2.4B | ||
| Q2 25 | $2.5B | $2.4B | ||
| Q1 25 | $2.5B | $2.4B | ||
| Q4 24 | $2.6B | $2.4B | ||
| Q3 24 | $2.7B | $7.0B | ||
| Q2 24 | $2.6B | $6.9B | ||
| Q1 24 | $2.6B | $7.7B |
| Q4 25 | $1.9B | $551.2M | ||
| Q3 25 | $1.8B | $399.5M | ||
| Q2 25 | $1.7B | $857.8M | ||
| Q1 25 | $1.7B | $1.5B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.6B | $3.0B | ||
| Q2 24 | $1.6B | $2.9B | ||
| Q1 24 | $1.6B | $2.8B |
| Q4 25 | $6.4B | $6.5B | ||
| Q3 25 | $6.0B | $6.4B | ||
| Q2 25 | $5.9B | $6.6B | ||
| Q1 25 | $5.8B | $7.3B | ||
| Q4 24 | $5.9B | $7.3B | ||
| Q3 24 | $5.8B | $13.7B | ||
| Q2 24 | $5.6B | $13.4B | ||
| Q1 24 | $5.7B | $13.7B |
| Q4 25 | 1.34× | 4.32× | ||
| Q3 25 | 1.38× | 5.95× | ||
| Q2 25 | 1.45× | 2.77× | ||
| Q1 25 | 1.50× | 1.59× | ||
| Q4 24 | 1.58× | 1.78× | ||
| Q3 24 | 1.65× | 2.35× | ||
| Q2 24 | 1.63× | 2.39× | ||
| Q1 24 | 1.64× | 2.77× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $231.6M | $1.1B |
| フリーキャッシュフロー営業CF - 設備投資 | $193.9M | $1.0B |
| FCFマージンFCF / 売上 | 5.5% | 41.5% |
| 設備投資強度設備投資 / 売上 | 1.1% | 1.7% |
| キャッシュ転換率営業CF / 純利益 | 3.00× | 1.93× |
| 直近12ヶ月FCF直近4四半期 | $394.7M | $1.6B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $231.6M | $1.1B | ||
| Q3 25 | $107.9M | $112.6M | ||
| Q2 25 | $49.1M | $446.8M | ||
| Q1 25 | $101.6M | $144.3M | ||
| Q4 24 | $90.6M | $506.0M | ||
| Q3 24 | $27.2M | $119.5M | ||
| Q2 24 | $-15.2M | $256.0M | ||
| Q1 24 | $-78.9M | $97.8M |
| Q4 25 | $193.9M | $1.0B | ||
| Q3 25 | $92.2M | $80.2M | ||
| Q2 25 | $24.7M | $411.5M | ||
| Q1 25 | $84.0M | $113.4M | ||
| Q4 24 | $75.3M | $475.1M | ||
| Q3 24 | $7.2M | $93.9M | ||
| Q2 24 | $-39.0M | $209.8M | ||
| Q1 24 | $-100.7M | $78.8M |
| Q4 25 | 5.5% | 41.5% | ||
| Q3 25 | 2.8% | 4.7% | ||
| Q2 25 | 0.8% | 23.9% | ||
| Q1 25 | 2.9% | 7.2% | ||
| Q4 24 | 2.5% | 21.6% | ||
| Q3 24 | 0.2% | 6.2% | ||
| Q2 24 | -1.4% | 13.2% | ||
| Q1 24 | -3.9% | 5.3% |
| Q4 25 | 1.1% | 1.7% | ||
| Q3 25 | 0.5% | 1.9% | ||
| Q2 25 | 0.8% | 2.0% | ||
| Q1 25 | 0.6% | 2.0% | ||
| Q4 24 | 0.5% | 1.4% | ||
| Q3 24 | 0.7% | 1.7% | ||
| Q2 24 | 0.9% | 2.9% | ||
| Q1 24 | 0.8% | 1.3% |
| Q4 25 | 3.00× | 1.93× | ||
| Q3 25 | 1.93× | 0.41× | ||
| Q2 25 | 1.74× | — | ||
| Q1 25 | 3.44× | 0.71× | ||
| Q4 24 | 5.66× | 1.63× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | -0.76× | 1.61× | ||
| Q1 24 | — | 0.70× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BTSG
| Medicare D | $1.1B | 32% |
| Commercial Insurance | $879.8M | 25% |
| Medicare C | $641.2M | 18% |
| Provider Services | $394.2M | 11% |
| Medicaid | $301.4M | 8% |
| Medicare A | $150.5M | 4% |
| Private And Other | $44.0M | 1% |
| Medicare B | $19.5M | 1% |
| Pharmacy Solutions And Provider Services Segments | $19.0M | 1% |
TPR
| Coach | $1.4B | 57% |
| Other | $787.0M | 31% |
| Kate Spade Company | $290.0M | 12% |
